<i>TP53</i> IVS3 16 bp Variant and Breast Cancer Risk in Western Mexican Women: A Case–Control Study

• Published in: Current Issues in Molecular Biology
• Main Authors: Mariana Araiza-Guzmán, Bricia M. Gutiérrez-Zepeda, Ana M. Saldaña-Cruz, Ingrid B. Montoya-Delgado, Diana Rubio-Delgado, Pablo Benítez-Villa, Diana M. Hernández-Corona, Adrian Daneri-Navarro, Alicia del Toro-Arreola, Jazmin Márquez-Pedroza, Antonio Quintero-Ramos, Betsabé Contreras-Haro
• Format: Article
• Language: English
• Published: MDPI AG 2025-09-01
• Subjects: rs17878362; p53; <i>TP53</i>; breast cancer
• Online Access: https://www.mdpi.com/1467-3045/47/9/744
• ISSN: 1467-3037; 1467-3045

Background: Mutations in the <i>TP53</i> gene can alter its tumor suppressor functions, thereby promoting oncogenic activity. The <i>TP53</i> IVS3 16 bp genetic variant overlaps with nucleotide sequences that can alter regulatory structures, potentially affecting its function. The aim of the present study was to evaluate the association between <i>TP53</i> IVS3 16 bp genetic variant and the risk of breast cancer (BC) in women from western Mexico. Methods: The study included 220 women diagnosed with BC and 198 cancer-free controls. Clinical and demographic data were collected through structured questionnaires and verified with medical records. Genotyping of the <i>TP53</i> IVS3 16 bp genetic variant was performed using polymerase chain reaction (PCR) and visualized on 6% polyacrylamide gels. Results: Compared to controls, women with BC more frequently reported a family history of the disease and menopausal status (<i>p</i> < 0.05). Genotypic analysis revealed that carriers of the D/I genotype and the combined D/I + I/I genotypes were associated with a reduced risk of BC in codominant (OR = 0.53; 95% CI 0.32–0.88) and dominant (OR = 0.57; 95% CI 0.35–0.93) models. Conclusions: The D/I and D/I + I/I genotypes in codominant and dominant models showed a lower risk against BC. More studies are needed to confirm these findings.